PBM
Psyence Biomedical Ltd (PBM)
Healthcare • NASDAQ • $4.25-0.40%
Key Fundamentals
- Symbol
- PBM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.25
- Daily Change
- -0.40%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $137.89
- 52W Low
- $1.92
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- 1.69
About Psyence Biomedical Ltd
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Company websiteResearch PBM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.